Lisa D. Earnhardt Sells 20,000 Shares of Intersect ENT Inc (XENT) Stock

Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $36.79, for a total value of $735,800.00. Following the transaction, the insider now owns 489,683 shares of the company’s stock, valued at approximately $18,015,437.57. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Intersect ENT traded down $0.15, hitting $37.05, during mid-day trading on Tuesday, MarketBeat.com reports. 143,300 shares of the company’s stock traded hands, compared to its average volume of 280,745. The company has a market capitalization of $1.09 billion, a P/E ratio of -66.16 and a beta of 0.76. Intersect ENT Inc has a one year low of $26.25 and a one year high of $42.95.

Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. The firm had revenue of $24.70 million for the quarter, compared to the consensus estimate of $23.66 million. Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.23) EPS. equities research analysts predict that Intersect ENT Inc will post -0.64 earnings per share for the current year.

XENT has been the subject of a number of analyst reports. ValuEngine upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Thursday, March 22nd. Guggenheim restated a “buy” rating on shares of Intersect ENT in a research report on Thursday, March 1st. Berenberg Bank initiated coverage on Intersect ENT in a research report on Friday, April 20th. They set a “buy” rating for the company. Finally, Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research report on Saturday, May 5th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Intersect ENT currently has a consensus rating of “Buy” and an average price target of $38.50.

A number of institutional investors have recently made changes to their positions in XENT. SG Americas Securities LLC bought a new stake in Intersect ENT during the 1st quarter valued at $132,000. Bank of Montreal Can bought a new stake in Intersect ENT during the 4th quarter valued at $135,000. UBS Group AG raised its stake in Intersect ENT by 81.1% during the 1st quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after acquiring an additional 2,096 shares in the last quarter. Aperio Group LLC bought a new stake in Intersect ENT during the 1st quarter valued at $213,000. Finally, Elkfork Partners LLC bought a new stake in Intersect ENT during the 4th quarter valued at $237,000. 88.54% of the stock is currently owned by hedge funds and other institutional investors.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply